EP2453236A3 - Indicateur de charge biologique et procédé de mesure de charge biologique - Google Patents

Indicateur de charge biologique et procédé de mesure de charge biologique Download PDF

Info

Publication number: EP2453236A3
Authority: EP; European Patent Office
Prior art keywords: csf; fatigue; stress; factors; agent
Prior art date: 2006-02-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP12154982A

Other languages

German (de)

English (en)

Other versions

EP2453236A2 (fr

Inventor

Atsuo Sekiyama

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-17

Filing date

2007-02-16

Publication date

2012-08-22

2007-02-16 Application filed by Individual filed Critical Individual

2012-05-16 Publication of EP2453236A2 publication Critical patent/EP2453236A2/fr

2012-08-22 Publication of EP2453236A3 publication Critical patent/EP2453236A3/fr

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 4
108050006947 CXC Chemokine Proteins 0.000 abstract 2
102000019388 CXC chemokine Human genes 0.000 abstract 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 2
239000003446 ligand Substances 0.000 abstract 2
230000003340 mental effect Effects 0.000 abstract 2
238000012360 testing method Methods 0.000 abstract 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
108010081589 Becaplermin Proteins 0.000 abstract 1
102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 1
101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
102100032367 C-C motif chemokine 5 Human genes 0.000 abstract 1
102100032366 C-C motif chemokine 7 Human genes 0.000 abstract 1
101710155834 C-C motif chemokine 7 Proteins 0.000 abstract 1
102100025248 C-X-C motif chemokine 10 Human genes 0.000 abstract 1
101710098275 C-X-C motif chemokine 10 Proteins 0.000 abstract 1
108700012434 CCL3 Proteins 0.000 abstract 1
-1 CSF-3 Proteins 0.000 abstract 1
102000000013 Chemokine CCL3 Human genes 0.000 abstract 1
108010055165 Chemokine CCL4 Proteins 0.000 abstract 1
102000001326 Chemokine CCL4 Human genes 0.000 abstract 1
108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
102100023688 Eotaxin Human genes 0.000 abstract 1
101710139422 Eotaxin Proteins 0.000 abstract 1
101150021185 FGF gene Proteins 0.000 abstract 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
102100037850 Interferon gamma Human genes 0.000 abstract 1
102000006992 Interferon-alpha Human genes 0.000 abstract 1
108010047761 Interferon-alpha Proteins 0.000 abstract 1
108010074328 Interferon-gamma Proteins 0.000 abstract 1
108090000174 Interleukin-10 Proteins 0.000 abstract 1
108090000177 Interleukin-11 Proteins 0.000 abstract 1
108010065805 Interleukin-12 Proteins 0.000 abstract 1
108090000176 Interleukin-13 Proteins 0.000 abstract 1
108090000172 Interleukin-15 Proteins 0.000 abstract 1
108050003558 Interleukin-17 Proteins 0.000 abstract 1
108090000171 Interleukin-18 Proteins 0.000 abstract 1
108010002350 Interleukin-2 Proteins 0.000 abstract 1
108010002386 Interleukin-3 Proteins 0.000 abstract 1
108090000978 Interleukin-4 Proteins 0.000 abstract 1
108010002616 Interleukin-5 Proteins 0.000 abstract 1
108090001005 Interleukin-6 Proteins 0.000 abstract 1
108010002586 Interleukin-7 Proteins 0.000 abstract 1
108090001007 Interleukin-8 Proteins 0.000 abstract 1
108010002335 Interleukin-9 Proteins 0.000 abstract 1
108090000099 Neurotrophin-4 Proteins 0.000 abstract 1
102100033857 Neurotrophin-4 Human genes 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000011156 evaluation Methods 0.000 abstract 1
108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 abstract 1
102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 abstract 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/304—Mood disorders, e.g. bipolar, depression
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/306—Chronic fatigue syndrome
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Measuring And Recording Apparatus For Diagnosis (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

EP12154982A 2006-02-17 2007-02-16 Indicateur de charge biologique et procédé de mesure de charge biologique Withdrawn EP2453236A3 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2006041633		2006-02-17
EP07714417.8A EP2006680B1 (fr)	2006-02-17	2007-02-16	Indicateur d'une charge biologique et procede permettant de mesurer la charge biologique

Related Parent Applications (2)

Application Number	Title	Priority Date	Filing Date
EP07714417.8A Division-Into EP2006680B1 (fr)	2006-02-17	2007-02-16	Indicateur d'une charge biologique et procede permettant de mesurer la charge biologique
EP07714417.8 Division		2007-02-16

Publications (2)

Publication Number	Publication Date
EP2453236A2 EP2453236A2 (fr)	2012-05-16
EP2453236A3 true EP2453236A3 (fr)	2012-08-22

Family

ID=38371648

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP07714417.8A Active EP2006680B1 (fr)	2006-02-17	2007-02-16	Indicateur d'une charge biologique et procede permettant de mesurer la charge biologique
EP12154982A Withdrawn EP2453236A3 (fr)	2006-02-17	2007-02-16	Indicateur de charge biologique et procédé de mesure de charge biologique

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP07714417.8A Active EP2006680B1 (fr)	2006-02-17	2007-02-16	Indicateur d'une charge biologique et procede permettant de mesurer la charge biologique

Country Status (20)

Country	Link
US (1)	US20100233818A1 (fr)
EP (2)	EP2006680B1 (fr)
JP (1)	JP5069213B2 (fr)
KR (1)	KR101473495B1 (fr)
CN (1)	CN101454669B (fr)
AU (1)	AU2007215739B2 (fr)
BR (1)	BRPI0707958B8 (fr)
CA (1)	CA2642706C (fr)
CY (1)	CY1115418T1 (fr)
DK (1)	DK2006680T3 (fr)
ES (1)	ES2474690T3 (fr)
HR (1)	HRP20140673T1 (fr)
IL (1)	IL193496A (fr)
MY (1)	MY151424A (fr)
NZ (1)	NZ571018A (fr)
PL (1)	PL2006680T3 (fr)
PT (1)	PT2006680E (fr)
RU (1)	RU2519324C2 (fr)
SI (1)	SI2006680T1 (fr)
WO (1)	WO2007094472A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8158374B1 (en)	2006-09-05	2012-04-17	Ridge Diagnostics, Inc.	Quantitative diagnostic methods using multiple parameters
CN102037355A (zh) *	2008-03-04	2011-04-27	里奇诊断学股份有限公司	基于多重生物标记物板块诊断和监测抑郁症
EP2272044A4 (fr) *	2008-03-12	2011-07-06	Ridge Diagnostics Inc	Biomarqueurs d'inflammation pour la surveillance de troubles de dépression
JP5219048B2 (ja) *	2008-09-17	2013-06-26	独立行政法人農業・食品産業技術総合研究機構	抗豚インターロイキン−１８抗体を用いた動物のストレス評価方法
EP2337866B1 (fr) *	2008-10-15	2014-07-30	Ridge Diagnostics, Inc.	Mappage sur hyperespace multidimensionnel de biomarqueur humain pour des troubles dépressifs
WO2010059709A2 (fr) *	2008-11-18	2010-05-27	Ridge Diagnostics, Inc.	Biomarqueurs de syndrome métabolique et d'axe hpa pour un trouble dépressif majeur
CA2757518A1 (fr) *	2009-04-01	2010-10-07	Ridge Diagnostics, Inc.	Biomarqueurs pour controler le traitement de maladies neuropsychiatriques
CN102460153A (zh) *	2009-04-06	2012-05-16	里奇诊断学股份有限公司	监控神经精神疾病治疗的生物标记
WO2010119769A1 (fr) *	2009-04-14	2010-10-21	片倉工業株式会社	Procédé d'évaluation du stress chronique
JP5553525B2 (ja) *	2009-04-17	2014-07-16	敦生関山	生体負荷の指標剤および生体負荷の測定方法
WO2011094308A2 (fr) *	2010-01-26	2011-08-04	Ridge Diagnostics, Inc.	Panels de marqueurs biologiques multiples pour stratifier la sévérité d'une maladie et pour surveiller le traitement d'une dépression
JP5821447B2 (ja) *	2011-09-13	2015-11-24	大正製薬株式会社	カルジオリピンを用いた疲労の判定方法
CN104937414A (zh) *	2012-10-24	2015-09-23	夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统)	用于鉴定肝损伤的生物标记
JP5710666B2 (ja) *	2013-02-25	2015-04-30	敦生関山	生体負荷の指標剤および生体負荷の測定方法
JP6205175B2 (ja)	2013-05-16	2017-10-04	株式会社Ｒｅｓｖｏ	精神・神経疾患バイオマーカー
CA3112130A1 (fr) *	2013-07-11	2015-01-15	University Of North Texas Health Science Center At Fort Worth	Depistage base sur le sang pour la detection d'une maladie neurologique dans des installations de soins primaires
AU2014354808A1 (en)	2013-11-26	2016-06-02	University Of North Texas Health Science Center At Fort Worth	Personalized medicine approach for treating cognitive loss
JPWO2015174544A1 (ja) *	2014-05-16	2017-04-20	国立研究開発法人国立精神・神経医療研究センター	精神疾患判定マーカー
CA2998533A1 (fr) *	2015-10-08	2017-04-13	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Biomarqueurs pour le diagnostic du trouble de stress post-traumatique
CN106814145B (zh) *	2016-12-20	2019-08-30	河北工程大学	一种人体疲劳测定方法
RU2630605C1 (ru) *	2017-01-09	2017-09-11	Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью	Способ оценки риска нарушения здоровья работников титано-магниевого производства, режим труда которых включает ночные смены
CN106706929B (zh) *	2017-01-22	2019-01-18	河北工程大学	一种利用唾液检测人体疲劳的方法
CN108333362B (zh) *	2017-12-21	2021-04-02	河北工程大学	一种人体疲劳测定方法
WO2019143562A1 (fr)	2018-01-18	2019-07-25	University Of North Texas Health Science Center At Fort Worth	Diagnostic compagnon pour ains et donépézil pour le traitement de sous-populations spécifiques de patients souffrant de la maladie d'alzheimer
WO2020241809A1 (fr) *	2019-05-31	2020-12-03	日本たばこ産業株式会社	Procédé d'évaluation de sensation de bonheur et procédé d'acquisition de données pour évaluer la sensation de bonheur
CN112716505A (zh) *	2020-12-08	2021-04-30	河北工程大学	一种快速的疲劳检测方法
CN113180595A (zh) *	2021-03-25	2021-07-30	河北工程大学	基于人体唾液蛋白测定重点行业职业疲劳程度的检测系统
CN113151443B (zh) *	2021-04-16	2022-07-01	中央民族大学	细胞因子联合分析作为精神分裂症标志物及其应用
JP7767055B2 (ja) *	2021-08-16	2025-11-11	株式会社Ｌｓｉメディエンス	精神ストレスの定量法
KR102530616B1 (ko) *	2022-09-22	2023-05-10	주식회사 메디푸드플랫폼	의과학 및 성분학 기반의 정신 상태 분석 장치, 방법 및 프로그램

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030224345A1 (en) *	2001-08-24	2003-12-04	Advanced Cell Technology	Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
WO2004009618A2 (fr) *	2002-07-18	2004-01-29	Crucell Holland B.V.	Production par recombinaison de melanges d'anticorps
WO2005017203A2 (fr) *	2003-07-11	2005-02-24	Yale University	Systemes et methodes permettant de diagnostiquer et de traiter des troubles psychologiques et des troubles du comportement
US20050208519A1 (en) *	2004-03-12	2005-09-22	Genenews Inc.	Biomarkers for diagnosing schizophrenia and bipolar disorder
US20050245557A1 (en) *	2003-10-15	2005-11-03	Pain Therapeutics, Inc.	Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
US7135458B1 (en) *	1995-11-15	2006-11-14	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
JP4004088B2 (ja) *	1995-09-26	2007-11-07	株式会社林原生物化学研究所	免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
JP2724987B2 (ja)	1994-11-15	1998-03-09	株式会社林原生物化学研究所	インターフェロン−γの産生を誘導するポリペプチド
JP2952750B2 (ja) *	1995-02-23	1999-09-27	株式会社林原生物化学研究所	モノクローナル抗体
US6207641B1 (en) *	1995-03-10	2001-03-27	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
JP4490576B2 (ja) *	1999-10-26	2010-06-30	富山化学工業株式会社	中枢神経系作用薬のスクリーニング方法及びストレス状態の評価方法
JP2005124565A (ja) *	2003-09-29	2005-05-19	Sogo Ikagaku Kenkyusho:Kk	新規神経ペプチド及びその利用
EP2177907B1 (fr)	2004-06-30	2014-01-01	Atsuo Sekiyama	Agent indicateur d'une réponse au stress non inflammatoire et son utilisation
JP4645939B2 (ja)	2004-07-22	2011-03-09	日本電気株式会社	移動基地局位置決定システム、端末位置決定システム、移動基地局、無線端末及び基地局位置決定プログラム

2007
- 2007-02-16 WO PCT/JP2007/052887 patent/WO2007094472A1/fr not_active Ceased
- 2007-02-16 HR HRP20140673TT patent/HRP20140673T1/hr unknown
- 2007-02-16 JP JP2008500573A patent/JP5069213B2/ja active Active
- 2007-02-16 PT PT77144178T patent/PT2006680E/pt unknown
- 2007-02-16 DK DK07714417.8T patent/DK2006680T3/da active
- 2007-02-16 BR BRPI0707958A patent/BRPI0707958B8/pt not_active IP Right Cessation
- 2007-02-16 PL PL07714417T patent/PL2006680T3/pl unknown
- 2007-02-16 NZ NZ571018A patent/NZ571018A/en not_active IP Right Cessation
- 2007-02-16 MY MYPI20083117 patent/MY151424A/en unknown
- 2007-02-16 SI SI200731482T patent/SI2006680T1/sl unknown
- 2007-02-16 CA CA2642706A patent/CA2642706C/fr active Active
- 2007-02-16 AU AU2007215739A patent/AU2007215739B2/en not_active Ceased
- 2007-02-16 RU RU2008137234/15A patent/RU2519324C2/ru active
- 2007-02-16 US US12/224,045 patent/US20100233818A1/en not_active Abandoned
- 2007-02-16 ES ES07714417.8T patent/ES2474690T3/es active Active
- 2007-02-16 CN CN2007800136014A patent/CN101454669B/zh not_active Expired - Fee Related
- 2007-02-16 EP EP07714417.8A patent/EP2006680B1/fr active Active
- 2007-02-16 EP EP12154982A patent/EP2453236A3/fr not_active Withdrawn
2008
- 2008-08-17 IL IL193496A patent/IL193496A/en active IP Right Grant
- 2008-09-16 KR KR1020087022617A patent/KR101473495B1/ko not_active Expired - Fee Related
2014
- 2014-07-11 CY CY20141100525T patent/CY1115418T1/el unknown

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030224345A1 (en) *	2001-08-24	2003-12-04	Advanced Cell Technology	Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy
WO2004009618A2 (fr) *	2002-07-18	2004-01-29	Crucell Holland B.V.	Production par recombinaison de melanges d'anticorps
WO2005017203A2 (fr) *	2003-07-11	2005-02-24	Yale University	Systemes et methodes permettant de diagnostiquer et de traiter des troubles psychologiques et des troubles du comportement
US20050245557A1 (en) *	2003-10-15	2005-11-03	Pain Therapeutics, Inc.	Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
US20050208519A1 (en) *	2004-03-12	2005-09-22	Genenews Inc.	Biomarkers for diagnosing schizophrenia and bipolar disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSUANG M T ET AL: "Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary report", AMERICAN JOURNAL OF MEDICAL GENETICS, WILEY, NEW YORK,NY, US, vol. 133B, no. 1, 5 February 2005 (2005-02-05), pages 1 - 5, XP002368087, ISSN: 0148-7299 *

Also Published As

Publication number	Publication date
RU2519324C2 (ru)	2014-06-10
CN101454669B (zh)	2013-11-20
CY1115418T1 (el)	2017-01-04
CN101454669A (zh)	2009-06-10
SI2006680T1 (sl)	2014-08-29
PT2006680E (pt)	2014-07-14
PL2006680T3 (pl)	2014-09-30
MY151424A (en)	2014-05-30
EP2006680A1 (fr)	2008-12-24
HRP20140673T1 (hr)	2014-10-10
BRPI0707958A2 (pt)	2011-05-17
RU2008137234A (ru)	2010-03-27
EP2453236A2 (fr)	2012-05-16
NZ571018A (en)	2012-03-30
BRPI0707958B1 (pt)	2018-10-16
DK2006680T3 (da)	2014-06-23
EP2006680A4 (fr)	2009-09-09
IL193496A0 (en)	2009-05-04
JPWO2007094472A1 (ja)	2009-07-09
AU2007215739B2 (en)	2014-01-16
US20100233818A1 (en)	2010-09-16
JP5069213B2 (ja)	2012-11-07
IL193496A (en)	2015-07-30
CA2642706A1 (fr)	2007-08-23
WO2007094472A1 (fr)	2007-08-23
EP2006680B1 (fr)	2014-04-16
CA2642706C (fr)	2017-08-01
HK1133461A1 (en)	2010-03-26
KR101473495B1 (ko)	2014-12-17
KR20090007289A (ko)	2009-01-16
AU2007215739A1 (en)	2007-08-23
BRPI0707958B8 (pt)	2021-07-27
ES2474690T3 (es)	2014-07-09

Legal Events

Date	Code	Title	Description
2012-05-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-05-16	AC	Divisional application: reference to earlier application	Ref document number: 2006680 Country of ref document: EP Kind code of ref document: P
2012-05-16	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2012-05-16	AX	Request for extension of the european patent	Extension state: HR
2012-07-20	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2012-08-22	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2012-08-22	AX	Request for extension of the european patent	Extension state: HR
2012-08-22	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/53 20060101AFI20120713BHEP Ipc: G01N 33/68 20060101ALI20120713BHEP
2013-03-08	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1170810 Country of ref document: HK
2013-03-27	17P	Request for examination filed	Effective date: 20130219
2013-05-01	17Q	First examination report despatched	Effective date: 20130403
2014-02-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2014-03-19	18D	Application deemed to be withdrawn	Effective date: 20131015
2019-09-20	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1170810 Country of ref document: HK

Publication	Publication Date	Title
EP2453236A3 (fr)	2012-08-22	Indicateur de charge biologique et procédé de mesure de charge biologique
Hicks et al.	2006	From Goals to Theory.
Jiang et al.	2020	Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics
Kothur et al.	2016	CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review
Slade et al.	2011	Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness
Langeskov-Christensen et al.	2014	Validity and reliability of VO2-max measurements in persons with multiple sclerosis
KR102061725B1 (ko)	2020-01-02	정신 건강을 진단하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체
Wong et al.	2012	Validation of the spinal nutrition screening tool (SNST) in patients with spinal cord injuries (SCI): result from a multicentre study
CN104042223A (zh)	2014-09-17	运动机能评价装置以及运动机能评价方法
Wolkow et al.	2016	Acute psychophysiological relationships between mood, inflammatory and cortisol changes in response to simulated physical firefighting work and sleep restriction
US11442068B2 (en)	2022-09-13	Method for diagnosing and treating fibromyalgia
CN119132606A (zh)	2024-12-13	一种儿童肥胖数据分析和预测方法及模型
CN119716055A (zh)	2025-03-28	可溶性因子在麻痹性痴呆检测中的应用
Reiss	2013	Reiss extramarital sexual permissiveness scale
Gochicoa‐Rangel et al.	2023	Lung function is related to salivary cytokines and hormones in healthy children. An exploratory cross‐sectional study
US8762168B2 (en)	2014-06-24	Method of defining the physical condition level
Bertochi et al.	2023	Validity of weekly and monthly perceived exertion in runners
CN205759573U (zh)	2016-12-07	一种立定跳远测试仪
Ennin et al.	2022	White Blood Cell Count and Serum Cytokine Profile in Tropical Hardwood Workers in Kumasi
CN201795967U (zh)	2011-04-13	测量齿轮/链轮侧齿面硬度的倾斜试台
Ilfeld Jr	1980	Age, stressors, and psychosomatic disorders
Ellis et al.	2006	The Australian Biomarkers Lifestyle and Imaging flagship study of ageing
Wootton et al.	2014	Contemporary Psychometric Evaluation of the ObsessiveCompulsive Inventory–Revised
Trümper et al.	2009	Heart rate-based protocols for exercise challenge testing do not ensure sufficient exercise intensity for inducing exercise-induced bronchial obstruction
Ferrari et al.	2026	Individual load-velocity relationship “in situ”: a novel approach for the characterization of muscle function and 1 RM estimation.